Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TOP2A | P11388 | 2/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.61 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476725 | 0.89 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL6055672 | 0.84 | NISCH (0.49) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL6055796 | 0.84 | NISCH (0.49) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1685409 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL8141372 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL17826831 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1209074 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2518908 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL771337 | 0.79 | NISCH (0.66) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL1886692 | 0.79 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224335-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | KIM SUNG-HEE | 2011-09-15 | — | — | US | claimed |
| US-7935552-B2 | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO., LTD. (KR) | 2011-05-03 | — | — | US | claimed |
| CN-101993632-A | Ink composition | DONGJIN SEMICHEM CO LTD | 2011-03-30 | — | — | CN | claimed |
| CN-101735690-A | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO LTD | 2010-06-16 | — | — | CN | claimed |
| US-20100120181-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2010-05-13 | — | — | US | claimed |
| WO-2022139594-A1 | AMIDES AND SOLVENT FREE METHOD FOR THEIR MANUFACTURE | KLINGELBERG PRODUCTS AS (NO) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022139593-A1 | AMIDINES AND SOLVENT FREE METHOD FOR THEIR MANUFACTURE | KLINGELBERG PRODUCTS AS (NO) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022139222-A1 | SELF-ADHESIVE FIRE-EXTINGUISHING TAPE COMPRISING FIRE-EXTINGUISHING MICROCAPSULES, AND FIRE-EXTINGUISHING PRODUCT USING SAME | 주식회사 지에프아이 | 2022-06-30 | — | — | WO | disclosed |
| US-20210238192-A1 | VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3235815-A1 | AGENTS AGAINST PARASITIC HELMINTHS | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-9169409-B2 | Ink composition for imprint lithography and roll printing | LG DISPLAY CO., LTD. (KR) | 2015-10-27 | — | — | US | disclosed |
| WO-2015087857-A1 | ARYL AMIDINE COMPOUND AND BACTERICIDAL AGENT | 日本曹達株式会社 | 2015-06-18 | — | — | WO | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| CN-101735690-A | Ink composition and method of fabricating liquid crystal display device using the same | LG DISPLAY CO LTD | 2010-06-16 | — | — | CN | disclosed |
| US-20100120181-A1 | INK COMPOSITION AND METHOD OF FABRICATING LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | LG DISPLAY CO., LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238192-A1 | VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF | VCAM1, VAPB, ICAM1 | NISCH 4828/4885LMNA 3490/4885RECQL 4682/4885 |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | NISCH 1820/4885LMNA 3675/4885RECQL 3178/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | NISCH 1820/4885LMNA 3675/4885RECQL 3178/4885 |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | NISCH 954/4885LMNA 685/4885RECQL 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.